Category: Pharma, Life Sciences & Med Tech Players
-
Bayer Xarelto cases: Denmark becomes interesting patent PI jurisdiction after first Supreme Court clarification of strong validity presumption
The top Danish court also spoke out on the impact of redundant patent claim elements.
-
Munich I Regional Court grants Regeneron preliminary injunctions against Advanz (21 European countries), Celltrion, Hexal, Stada
Regeneron used a patent that previously secured injunctions against Formycon.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technology
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
China’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.
-
Novo Nordisk suffers another loss in efforts to extend key Ozempic patent in Brazil
Brazil’s Superior Tribunal de Justiça has issued its first-ever decision on patent term adjustment, ruling that Novo Nordisk’s request to extend its Ozempic-related patent is unconstitutional because a drugmaker’s rights to a patent term cannot override society’s rights to affordable medicine.
-
Abbott regains key patent from now-settled Dexcom dispute as EWCA issues rare patent revocation reversal
The England & Wales Court of Appeal has reversed a lower court’s decision to revoke a patent asserted in Abbott’s now-settled global patent dispute with Dexcom, handing the continuous glucose monitor device maker another key win.
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Lawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.
-
Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC
Following President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…
-
Some direct patent infringement “acceptable price” for expediting competition: U.S. Solicitor General urges Supreme Court to review skinny labeling and generic drug access
United States Solicitor General D. John Sauer has filed a petition urging the Supreme Court to intervene in a long-running drug patent infringement case in which he alleges the Federal Circuit failed to apply the “skinny labelling” (section viii) pathway, which allows the entry of generics that carve out patented uses but otherwise duplicate the…
-
UPC’s Roche-Menarini preliminary injunction clarifies relationship between independent product and manufacturing method claims
An independent method claim cannot, without more, result in further requirements for the infringement of an independent product claim.